*Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use

Guthrie, B. ., Rogers, G. ., Livingstone, S. ., Morales, D. R., Donnan, P. ., Davis, S. ., … Payne, K. . (2024). The implications of competing risks and direct treatment disutility in cardiovascular disease and osteoporotic fracture: risk prediction and cost effectiveness analysis. Health Soc Care Deliv Res, 12, 1–275. http://doi.org/10.3310/kltr7714
Morgan, C. L., Durand, A. ., McCormack, T. ., Hughes, E. ., Berni, T. R., & Lahoz, R. . (2023). Risk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the CPRD. BMJ Open, 13, e064541. http://doi.org/10.1136/bmjopen-2022-064541
Tammes, P. ., Payne, R. A., & Salisbury, C. . (2022). Association between continuity of primary care and both prescribing and adherence of common cardiovascular medications: a cohort study among patients in England. BMJ Open, 12, e063282. http://doi.org/10.1136/bmjopen-2022-063282